The U.S. Court of Appeals for the Federal Circuit recently ruled in the patent case Edge Systems LLC v. Cartessa Aesthetics, LLC, docket number 25-1119. The court decided to vacate a lower court's ruling that found Cartessa did not infringe on Edge's patent while affirming that the patent was not invalid. This decision affects both companies involved in the skin treatment technology industry and could have broader implications for patent law.
Edge Systems, a company specializing in aesthetic treatment devices, accused Cartessa Aesthetics of infringing on its U.S. Patent No. 9,550,052, which pertains to a system for skin treatment. The patent describes a system that includes a manifold designed to control the flow of treatment materials from multiple fluid containers. Edge claimed that Cartessa's Skinwave system violated this patent. The case was filed in December 2020 in the U.S. District Court for the Eastern District of New York.
In the lower court, both parties sought summary judgment, with Edge arguing that Cartessa's Skinwave system infringed its patent and Cartessa asserting that the patent was invalid. The district court ruled in favor of Cartessa, granting summary judgment for noninfringement and also ruling that the patent was not invalid. Edge appealed the noninfringement ruling, while Cartessa cross-appealed the ruling on invalidity.
The Federal Circuit's ruling addressed two main issues: the noninfringement claim and the validity of the patent. The court vacated the lower court's summary judgment on noninfringement, stating that the district court did not adequately resolve the dispute over the meaning of the term "manifold." The court noted, "however one might construe the functions of a manifold, Edge cannot prove that the Skinwave device contains one." This indicates that the definition of "manifold" is crucial to determining whether Cartessa's system infringes Edge's patent.
In its decision, the Federal Circuit emphasized the need for the district court to clarify the meaning of "manifold" and to reassess the evidence regarding the Skinwave system's compliance with the patent's claims. The court stated that a reasonable jury could find that Edge's interpretation of the term is valid, which could lead to a different outcome regarding infringement.
On the issue of patent validity, the Federal Circuit affirmed the lower court's ruling that the patent was not invalid. The court concluded that no reasonable jury could find by clear and convincing evidence that Cartessa's prior patent, U.S. Patent No. 6,162,232, anticipated Edge's patent. The court noted that the prior patent did not disclose the capability for a user to select treatment materials from multiple containers, which is a requirement of Edge's patent.
This ruling has significant implications for both Edge Systems and Cartessa Aesthetics. For Edge, the vacating of the noninfringement ruling means that the case will return to the lower court for further proceedings, potentially allowing Edge to present more evidence or arguments regarding the infringement claim. For Cartessa, the affirmation of no invalidity provides some protection for its Skinwave system, at least in terms of the patent's validity.
The decision also highlights the importance of precise language and definitions in patent law. The outcome of the case could set a precedent for how terms like "manifold" are interpreted in future patent disputes, particularly in the field of medical devices and aesthetic treatments.
Looking ahead, the case will return to the district court for further examination of the infringement claims based on the clarified definition of "manifold." Both parties may continue to explore their legal options, including the possibility of further appeals depending on the outcome of the proceedings. The court's ruling emphasizes the ongoing complexities in patent litigation and the critical nature of claim construction in determining infringement and validity.














